4564.T OncoTherapy Science (JPX) down 8.70% pre-market 24 Mar 2026: active volume insight

Pre-market trading shows 4564.T stock at JPY 21.00, down -8.70% on heavy volume of 66,352,100.00 shares on the JPX in Japan. This sharp move makes OncoTherapy Science, Inc. one of the most active names in the pre-market session on 24 Mar 2026. Market participants are pricing clinical and liquidity factors, with the stock trading below its 200-day average JPY 23.90 and above the year low JPY 19.00. We track fundamentals, technicals, and Meyka AI signals to explain the trade and near-term outlook.

Pre-market action and trading stats for 4564.T stock

OncoTherapy Science (4564.T) opened at JPY 22.00 and is trading JPY 21.00 pre-market, a -2.00 yen move from yesterday. Volume at 66,352,100.00 equals a relative volume of 2.23, well above the average 41,499,891.00 shares, marking it among the most active JPX names today. The intraday range is JPY 20.00–22.00, year range JPY 19.00–35.00, and market cap stands at JPY 7,903,802,777.00.

Fundamentals and valuation snapshot for 4564.T stock

OncoTherapy shows negative earnings with EPS -2.83 and a trailing PE of -8.13, reflecting losses. The price-to-book ratio is 3.88 and price-to-sales is 10.08, indicating premium pricing against revenue. Cash per share is JPY 6.06 and book value per share is JPY 5.93, while current ratio is 8.51, showing a strong liquidity buffer for a biotech firm.

Clinical pipeline and news drivers behind 4564.T stock moves

OncoTherapy’s pipeline includes Phase III peptide vaccine S-588410 and small molecules OTS167 and OTS964, which drive sentiment. Any trial update or regulatory news tends to move the stock sharply, given the small-float, high-share-count dynamic. For company filings and background see the corporate site and latest market metrics from Reuters source and OncoTherapy.

Technical setup and volume indicators for 4564.T stock

Momentum indicators show RSI 64.35 and MACD histogram 0.21, suggesting short-term strength despite the pre-market drop. Bollinger Bands sit 19.26–23.74, placing current price near the middle band. High on-balance volume and MFI 75.48 confirm buying pressure earlier this month, while ATR 1.32 underlines elevated intraday volatility.

Meyka AI grade, forecast and model view on 4564.T stock

Meyka AI rates 4564.T with a score out of 100: 69.19 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of JPY 17.31 and a quarterly target of JPY 15.60, compared with the current JPY 21.00, implying downside near -17.57% to the yearly projection. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context for 4564.T stock

Key catalysts include Phase III readouts and partner deals that could lift valuation toward the year high JPY 35.00. Principal risks are negative EPS, high valuation metrics, and trial setbacks common to biotechnology. Healthcare sector peers trade with average PE 23.19; OncoTherapy’s negative PE and premium PB require clinical success to justify multiple expansion.

Final Thoughts

4564.T stock is the most active JPX name pre-market on 24 Mar 2026 after a -8.70% drop to JPY 21.00, driven by heavy volume 66,352,100.00 and profit-taking on near-term clinical uncertainty. Our review balances strong liquidity metrics—cash per share JPY 6.06 and current ratio 8.51—against negative EPS -2.83 and elevated valuation multiples like P/S 10.08 and P/B 3.88. Price targets: Bear JPY 15.60, Base JPY 17.31, Bull JPY 30.00, reflecting trial success scenarios and the stock’s year high JPY 35.00. Meyka AI’s forecast model projects a yearly level of JPY 17.31, implying roughly -17.57% versus the current price JPY 21.00; forecasts are model-based and not guarantees. Traders focused on pre-market liquidity should watch trial announcements, Reuters market metrics, and our internal Meyka stock page for live updates Meyka stock page. As an AI-powered market analysis platform, Meyka AI flags 4564.T for active trading but recommends monitoring clinical catalysts before adding exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.